Development of a biomarker for penconazole: a human oral dosing study and a survey of UK residents’ exposure by Sams, Craig et al.
Development of a biomarker for penconazole: a human oral dosing study and a survey
of UK residents’ exposure
Sams, Craig ; Jones, Kate; Galea, Karen; MacCalman, Laura; Cocker, John; Teedon, Paul;








Publisher's PDF, also known as Version of record
Link to publication in ResearchOnline
Citation for published version (Harvard):
Sams, C, Jones, K, Galea, K, MacCalman, L, Cocker, J, Teedon, P, Cherrie, JW & van Tongeren, M 2016,
'Development of a biomarker for penconazole: a human oral dosing study and a survey of UK residents’
exposure', Toxics, vol. 4, no. 2, 10. https://doi.org/10.3390/toxics4020010
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 29. Apr. 2020
toxics
Article
Development of a Biomarker for Penconazole: A
Human Oral Dosing Study and a Survey of UK
Residents’ Exposure
Craig Sams 1, Kate Jones 1,*, Karen S. Galea 2, Laura MacCalman 2, John Cocker 1, Paul Teedon 3,
John W. Cherrie 2,4 and Martie van Tongeren 2
1 Health and Safety Laboratory (HSL), Buxton SK17 9JZ, UK; craig.sams@hsl.gsi.gov.uk (C.S.);
john.cocker@hsl.gsi.gov.uk (J.C.)
2 Centre for Human Exposure Science, Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK;
karen.Galea@iom-world.org (K.S.G.); Laura.MacCalman@iom-world.org (L.M.);
john.cherrie@iom-world.org (J.W.C.); Martie.VanTongeren@iom-world.org (M.T.)
3 School of Engineering and the Built Environment, Glasgow Caledonian University, Glasgow G4 0BA, UK;
Paul.Teedon@gcu.ac.uk
4 Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot Watt University,
Edinburgh EH14 4AS, UK
* Correspondence: kate.jones@hsl.gsi.gov.uk; Tel.: +44-129-821-8435
Academic Editor: Christos Damalas
Received: 16 March 2016; Accepted: 5 May 2016; Published: 13 May 2016
Abstract: Penconazole is a widely used fungicide in the UK; however, to date, there have been no
peer-reviewed publications reporting human metabolism, excretion or biological monitoring data.
The objectives of this study were to i) develop a robust analytical method, ii) determine biomarker
levels in volunteers exposed to penconazole, and, finally, to iii) measure the metabolites in samples
collected as part of a large investigation of rural residents’ exposure. An LC-MS/MS method was
developed for penconazole and two oxidative metabolites. Three volunteers received a single oral
dose of 0.03 mg/kg body weight and timed urine samples were collected and analysed. The volunteer
study demonstrated that both penconazole-OH and penconazole-COOH are excreted in humans
following an oral dose and are viable biomarkers. Excretion is rapid with a half-life of less than
four hours. Mean recovery of the administered dose was 47% (range 33%–54%) in urine treated
with glucuronidase to hydrolyse any conjugates. The results from the residents’ study showed that
levels of penconazole-COOH in this population were low with >80% below the limit of detection.
Future sampling strategies that include both end of exposure and next day urine samples, as well as
contextual data about the route and time of exposure, are recommended.
Keywords: penconazole; urine; biomarkers; fungicide; spray; residents; exposure;
biological monitoring
1. Introduction
Penconazole (1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole) is a systemic triazole fungicide
with preventive and curative properties for the control of powdery mildew [1]. It is used within the
European Union on fruit and vegetable crops, particularly apples, hops and soft fruit; in the UK, in
2015, there were ten products authorised for professional use [2]. In the review of penconazole by the
World Health Organisation in 1992, an acceptable daily intake (ADI) of 0.03 mg/kg body weight/day
was determined [1], and a more recent re-evaluation by the European Food Safety Agency (EFSA)
has proposed the same ADI value [3]. Potential human health effects arising from exposure have not
been well characterised, although penconazole has been linked with an endocrine disrupting mode of
Toxics 2016, 4, 10; doi:10.3390/toxics4020010 www.mdpi.com/journal/toxics
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action [4] and it is classified under the Global Harmonised System as H302: Harmful if swallowed
(Acute toxicity, oral—Category 4) and H361: Suspected of damaging fertility or the unborn child
(Reproductive toxicity—Category 2) [5]. In the UK, there remains public concern and debate regarding
exposure to pesticides and the potential exposure of residents living close to agricultural land has been
investigated recently [6–8]. A goal of this type of study is to determine appropriate biomarkers of
pesticide exposure in human samples and to compare the relative amount of those biomarkers found
to what might be anticipated from low-level human exposure at the ADI. Penconazole was identified
in that study as one of the commonly used pesticides in UK orchards and, as such, there is potential
that rural residents may be exposed. Penconazole is a widely used fungicide in the UK, with usage
increasing since 2012, and it is currently the sixth most abundantly used pesticide in UK orchards
(nearly 39,000 spray hectares in 2014 [9]).
Biological monitoring is a useful approach for determining exposure to chemicals and may be
particularly useful for population-based exposure assessment where large numbers of non-invasive
samples, such as urine, can be obtained relatively simply. It is also suitable for monitoring occupational
exposure, since it enables the determination of the actual absorbed amount of chemical in an individual,
accounting for any personal protective equipment such as protective clothing or respirator, dermal
absorption or ingestion. However, such an approach requires an appreciation of metabolism and
toxicokinetics (to identify a biomarker and an appropriate sample collection time), a suitable analytical
method and an appropriate reference range in order to interpret the data. Animal studies have
elucidated a number of potential urinary metabolites for penconazole [1] and an immunoassay
has been reported for detecting a metabolite (4-(2,4-Dichlorophenyl)5-(H-1,2,4-triazol-1-yl)pentoic
acid, penconazole-COOH) in spiked human urine [10]; however, no human exposure data have
been published. From animal data, two oxidative metabolites were identified as candidate urinary
biomarkers in humans (Figure 1). In addition, animal metabolism data indicate that excretion of
penconazole and its metabolites was mostly complete within the first 24 h [1].
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Figure 1. he ical structure of penconazole and its etabolites.
Human volunteer exposure studies can be helpful in establishing levels of biomarkers that may
be expected following exposure to a defined dose of a substance. The Health and Safety Laboratory
has previously conducted several such studies using a range of pesticides [11–13]. A similar approach
has been used here, involving administering a single oral dose of penconazole to volunteers at the
acceptable daily intake (ADI) of 0.03 mg/kg [1,3] and determining their urinary metabolite levels.
The objectives of the present study were to develop a robust analytical method for quantifying
penconazole metabolites in human urine, then to determine biomarker levels in volunteers exposed
to a single oral dose of penconazole at the ADI and, finally, to compare this data with measured
metabolite levels in samples collected as part of a large investigation of rural residents’ exposure [6–8],
in which penconazole was one of five target pesticides.
2. Experimental Section
. . e icals
li penconazole was obtained from QMX Laborat ries (Thaxted, UK). Solid penconazole-COOH
metabolite (4-(2,4-dichlorophenyl)5-(H-1,2,4-triazol-1-yl)pentoic acid) was obtained from Syngenta
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Crop Protection AG (Basel, Switzerland). A small aliquot of working solution containing
penconazole-OH was obtained from Professor Silvia Fustinoni (University of Milan). All solvents and
reagents used were of analytical grade.
2.2. Sample Preparation
Urine samples were stored frozen (´15 to ´20 ˝C) and defrosted in a water bath prior to analysis.
Calibration standards were prepared in glass screw-capped tubes using urine from an individual with
no known overt exposure to penconazole by adding the appropriate volume of working solution m
methanol; stored refrigerated) to 2 mL urine to achieve a concentration range from 10—100 µg/L.
Samples (2 mL) were analysed in duplicate and pairs of quality control (QC) samples, stored as
frozen aliquots, were analysed after each block of five duplicate samples. One millilitre of an enzyme
solution (250 µL β-glucuronidase from Helix pomatia (ě100,000 units/mL, Sigma Aldrich, Gillingham,
UK) diluted in 50 mL 0.1 M acetate buffer, pH 5) was added to all samples, standards and QCs and
incubated overnight at 37 ˝C.
To all tubes, 1 mL 0.2% phosphoric acid was added followed by liquid-liquid extraction using 4 mL
ethyl acetate. Tubes were capped and mixed for 20 minutes, followed by centrifuging for 5 minutes.
The organic layer (3 mL) was transferred to polypropylene tubes and evaporated to dryness under a
stream of nitrogen. Samples were reconstituted in 100 µL mobile phase.
2.3. Sample Analysis
Samples were analysed using liquid-chromatography with tandem mass-spectrometry detection
in selected reaction monitoring (SRM) mode (AB Sciex 3200 LC-MS/MS coupled to a Shimadzu
Prominence LC). A 10-µL sample was injected onto a Genesis c18 column (100 ˆ 2 mm, 3 µm; Jones
Chromatography) and eluted using mobile phase containing 70:30 methanol: 10 mM ammonium
formate (0.1% formic acid) at 0.2 mL per minute. The mass spectrometer was operated in positive
electrospray ionisation mode and the SRM m/z transitions were 284.2/69.9 for penconazole, 300.1/70
for penconazole-OH and 314.0/70.1 for penconazole-COOH using 200 ms dwell times. Source
temperature was set at 350 ˝C, ion spray voltage was 5000 V and gas flows were as follows: curtain
gas 10 L/min; collision gas 5 L/min; ion source gas 1 and 2 20 L/min. Compound-specific mass
spectrometer voltages were obtained using the instrument’s autotune function.
2.4. Method Characteristics
The method was linear beyond 100 µg/L (least squares regression coefficient >0.99). Repeated
analysis of QC samples gave inter-assay variations of 20% for penconazole and 15% for
penconazole-COOH. Intra-assay variations were below 10%. Due to the very limited amount of
penconazole-OH available, this compound was not added to QC material; however, calibration
standards were run at the end of the batch to check that instrumental drift was acceptable. Detection
limit for penconazole-COOH was determined as 0.25 µg/L based on three times signal to noise.
Example chromatograms are given in Figure 2.
2.5. Creatinine Analysis
Creatinine was determined in all urine samples using an automated alkaline picrate method
(Jaffe reaction) using a Pentra 400 clinical analyser (ABX, France) [14]. The coefficient of variation for
within-day analysis was 1.5% and for between-day analysis was 3% at 6 mM. Data were adjusted
for creatinine levels to account for hydration status and creatinine-corrected results were used for all
data analysis.
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2.6. Volunteer Study
The protocol used in this study was approved by the University of Sheffield Research Ethics
Committee (study number HSL09, 2014). After giving informed written consent, three volunteers were
given a single oral dose of penconazole at the ADI (0.03 mg/kg) dissolved in ethanol and diluted with
a soft drink. Volunteer details are shown in Table 1. Total urine excreted was collected into a series of
labelled containers for 24 h pre-dose and 48 hours post-dose. Pre- and post-dose collections covered
the time periods 0–2, 2–4, 4–6, 6–8, 8–12, 12–20, 20–24 h with the post-dose collections additionally
covering 24–28, 28–32, 32–36, 36–44 and 44–48 h post-exposure. The midpoint of each time period was
used when data were plotted on graphs. The volume of each sample was recorded and an aliquot
retained for analysis.
Table 1. Details of the volunteers for the oral dose study.
Code Sex Height (m) Weight (kg) Age (Years) BMI*
A M 1.78 72 59 22.7
B F 1.58 62 50 24.8
C M 1.88 83 62 23.5
* Body Mass Index.
2.7. Residents’ Study
A study was conducted of residents living within 100 m of agricultural land that had been
identified as likely to be subject to pesticide spraying. The overall study design has been described
in detail elsewhere [7,8]. The study received full ethical approval by the NHS South East Scotland
Research Ethics Committee (SESREC) 3 (study number 10/S1103/63). In brief, sample and data
collection took place in three major arable crop growing and orchard areas in Great Britain: East
Lothian, Kent, and Norfolk. Farmers were recruited into the study if they were likely to spray their
agricultural crops with selected pesticides (captan, chlormequat, chlorpyrifos, cypermethrin and
penconazole) and there were residential areas within 100 m of the fields being sprayed. The farmers
provided details of their pesticide usage. Residents (adults aged 18 years and over and children in
their care aged 4-12 years) were invited to participate in the study if they lived within 100 m of any
field belonging to a enlisted farm. Participants provided informed written consent. First morning void
urine samples were collected within two days after a spray event from participating residents, as well
as a number of first morning void samples that were not associated with spray events (background
samples collected during and outside of the spray season, with the spray season being taken to be
March–August, 2011 and 2012). These urine samples were frozen soon after collection and stored
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at ´15 to ´20 ˝C prior to analysis. Urine samples associated with a spraying event were analysed only
for the relevant pesticide(s) sprayed. Background samples were measured for all pesticides selected for
the study. Participants were also asked to complete a questionnaire about the previous two days at the
time of providing each urine sample; providing information on home and para-occupational pesticide
usage, outdoor and indoor activities and their duration as well as home grown produce consumption.
The analytical methods and sample results for chlormequat, chlorpyrifos, captan and
cypermethrin are described in detail in the project report [15]. The analytical method for
penconazole (as detailed here) was also described there although samples were only analysed for
penconazole-COOH and were not hydrolysed (the analysis took place before the volunteer study).
Penconazole-COOH was quantified using multipoint matrix-matched calibration curves (including a
blank) and QC samples (matrix spikes) were run every five samples (coefficient of variation = 14.9%,
n = 308). Mean values were reported from duplicate analyses. Urine samples with detectable
penconazole-COOH were reanalysed at intervals to assess sample stability. No sample degradation
was observed over the evaluation period of 31 months.
3. Results
3.1. Volunteer Study
Only one of the pre-dose samples showed detectable penconazole-COOH levels (0.3 µmol/mol
creatinine; 4.5% of samples collected), whereas 73% of pre-dose samples were detectable for hydrolysed
penconazole-OH (up to 8.2 µmol/mol creatinine). Post-dose urinary excretion of both penconazole
metabolites was complete within 48 hours of the oral dose. Quantifiable levels of metabolites
(penconazole-OH and penconazole-COOH) were found in all but one of the volunteer exposure
samples (see example in Figure 2), although levels were back within the pre-dose range in the
latter sample collections. Figure 3 shows the time course of urinary excretion of both metabolites
following hydrolysis of urine with β-glucuronidase. Peak urinary concentrations were found between
0–2 h post-dose.
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The mean peak penconazole-OH and penconazole-COOH concentrations were 1291 µmol/mol 
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Table 2. Urinary metabolite excretion half-lives calculated from three volunteers exposed to a single 
oral dose of penconazole at the acceptable daily intake (ADI) of 0.03 mg/kg body weight. 
 Mean Half-Life (h) Range (h) 
Penconazole-OH 3.1 2.6–3.5 
Penconazole-COOH 3.7 2.9–4.0 
Figure 3. rinary excretion of penconazole metabolites (penconazole-COOH (a) and penconazole-OH
(b)) in hydrolysed urine (mean +/- standard deviation; n = 3). One volunteer did not produce a sample
at the 2–4 hour time-point.
The mean peak penconazole-OH and penconazole-COOH concentrations were 1291 µmol/mol
(1177 µg/L) and 214 µmol/mol (200 µg/L), respectively (hydrolysed). Excretion half-lives are shown
in Table 2 with an example plot for a single volunteer shown in Figure 4.
Mean recovery of the administered dose was 47% (range 33%–54%) in urine treated with
glucuronidase to hydrolyse any conjugates. Data for hydrolysed urine are shown in Table 3.
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Table 2. Urinary metabolite excretion half-lives calculated from three volunteers exposed to a single
oral dose of penconazole at the acceptable daily intake (ADI) of 0.03 mg/kg body weight.
Mean Half-Life (h) Range (h)
Penconazole-OH 3.1 2.6–3.5
Penconazole-COOH 3.7 2.9–4.0Toxics 2016, 4, 10 6 of 10  
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Table 3. Recovery of urinary metabolites within 48 h of an oral dose, following hydrolysis.
Code % Administered DoseRecovered in Urine
Metabolite Fraction of Total
Pencon-OH Pencon-COOH Penconazole
A 53 0.85 0.15 0.001
B 54 0.87 0.13 0.001
C 33 0.77 0.23 0.002
Penconazole-OH was the major metabolite in hydrolysed urine, comprising approximately 80% of
the total metabolites. Very low levels (less than 0.5% of the dose) of un-metabolised penconazole were
recovered. In contrast, un-hydrolysed urine contained very different ratios of metabolites (Figure 5).
Less than 1% of the penconazole-OH metabolite was present in urine as un-conjugated metabolite. One
volunteer (C) did not excrete any detectable un-conjugated penconazole-OH. However, 80% (range
69%–97%) of penconazole-COOH was present in urine as free metabolite.
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Due to the novel biomarkers monitored and the lack of commercial standards or quality
assurance samples, a subset of volunteer study samples were also analysed by Professor Silvia
Fustinoni (University of Milan). There was reasonable agreement between the two laboratories
for penconazole-OH (slope = 0.885, r = 0.897, n = 14) and penconazole-COOH (slope = 1.244,
r = 0.872, n = 17).
3.2. Residents’ Study
Penconazole was sprayed only in the orchards recruited in the Kent region of this particular
study. Nine farms participated and 33 spray events involving this pesticide were noted during the
two spray seasons monitored. Forty-eight adults and six children were eligible participants providing
penconazole spray event related urine samples.
Before any data analysis of the urinary metabolite concentrations took place, a number of necessary
exclusions were made based on pre-defined eligibility for inclusion in the study (at least one spray
event related sample and at least one background). Urine samples where the creatinine level was
below 2 or greater than 30 mmol/L (0.23 g/L and 3.39 g/L, respectively) were excluded [7,8]. From
the penconazole spray events, 89 urine samples were collected from residents. In addition, 556
within season and 483 outwith season background urine samples were collected from the wider
study population.
A very high proportion of samples was below the analytical limit of detection (LOD) for
penconazole-COOH (81% following spray events and 89% at other times) and so only the proportion of
detects, the 95th percentile and the maximum level are reported in Table 4. Due to the high proportion
of non-detects no further analysis of questionnaire responses or modelling was performed [6].
Table 4. Summary of the urine results (unhydrolysed penconazole-COOH, µmol/mol creatinine) from
the residents’ study [15].
Sample Type N N < LOD %<LOD Maximum 95th Percentile *
Background sample—Outwith spray season 483 427 88 1.73 0.22
Background sample—Within spray season 556 500 90 1.19 0.29
After spray event 89 72 81 1.84 0.32
N = number; LOD = Limit of Detection; * of all data.
4. Discussion
Penconazole is a widely used fungicide in the UK [9] and this paper presents the
first journal-published human data demonstrating the urinary excretion of two metabolites of
penconazole that represent a significant percentage of an orally administered dose (penconazole-OH
and penconazole-COOH). Thus, these metabolites could be utilised as markers of systemic
exposure to penconazole. Penconazole-OH was excreted almost entirely as conjugates, whereas
penconazole-COOH was excreted primarily (>69%) as the free form in human volunteers. Fustinoni
has presented work at the 31st ICOH conference [16] and the 2015 International Congress on Rural
Health [17] looking at exposures to agriculture workers. The peak excretion values measured by
Fustinoni were 258 µg/L and 20 µg/L for penconazole-OH and penconazole-COOH, respectively
compared with 1291 µg/L and 232 µg/L, respectively, following a single oral dose at the ADI
(0.03 mg/kg/day), all after hydrolysis. Based on these comparisons, and the demonstration in our
work that hydrolysed penconazole-OH and penconazole-COOH are major metabolites in human urine,
the results of Fustinoni indicate that the internal dose to workers under the conditions of their study
was likely to be less than 0.03 mg/kg/day.
The analytical method presented here for penconazole-COOH (the lack of a standard prevented
characterisation of the method for penconazole-OH) is sensitive (LOD 0.25 µg/L, at least 300 times
lower than the peak urinary concentration following an ADI oral dose), reproducible (inter-assay
variation < 15%, n = 308) and robust (over 1100 samples analysed over 31 months, no deterioration
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of samples upon frozen storage [15]). The LOD was comparable with that reported for other triazole
fungicides [18] and the other pesticides measured in the residents’ study [7].
The volunteer study has demonstrated that both penconazole-OH and penconazole-COOH are
excreted by humans following an oral dose, confirming the data presented by Fustinoni et al. [16,17].
Peconazole-OH is excreted largely conjugated and as such is a significant metabolite (25%–47% of the
administered dose). Penconazole-COOH is excreted largely unconjugated and accounts for 7%–8%
of the dose (with seemingly less variation between volunteers although the sample size is small).
The ratio of the metabolites is similar to that found by Fustinoni [18] in vineyard workers exposed
to tebuconazole, with a ratio of tebuconazole-OH : tebuconazole-COOH of 3.5:1 (after hydrolysis).
We found the peak excretion of metabolites after an oral dose of penconazole occurred within 2 h
and was followed by elimination with a half-life of <4 h, whereas studies of occupational exposure
to tebuconazole found peak excretion occurred 16–24 h after exposure, possibly due to dermal
exposure [18,19] where absorption, and hence excretion, can be significantly delayed. The short
half-life of the penconazole metabolites after oral dosing would suggest a monitoring strategy for
inhalation and oral exposures would be to collect end of exposure samples. Where there is potential
for dermal exposure samples should also be collected the following day (e.g., first morning void), to
determine if peak levels occur at a later interval (as seen with tebuconazole worker studies). However,
the LOD for penconazole-COOH is almost three orders of magnitude lower than the peak level seen
in the volunteer study so if residents were exposed to penconazole, even at levels below the ADI,
metabolites should be detectable in urine samples collected within 4 to 5 half-lives; the volunteer study
showed levels at least 10ˆ the LOD at 24 h post-dose. Furthermore, it is likely that if residents were
exposed to penconazole it would be mostly through dermal exposure [20] rather than ingestion, with
the delay in peak exposure as seen in the tebuconazole study [18,19]. In these scenarios, collecting
urine samples the following day would increase the likelihood of detection in samples collected the
following day. However, the risk assessment model [6] suggested that the primary exposure route
would be “inhalation following volatilisation of the pesticide after spray event” so both scenarios
should be considered in designing a sampling approach in future studies.
The results from the residents’ study showed that levels of penconazole-COOH in this population
were low with >80% below the LOD. This is supported by the pre-dose volunteer samples where there
were 95% of results below the LOD. The maximum result from the residents’ study was 1.8 µmol/mol
creatinine, which is at least 100ˆ lower than the peak excretion after an oral dose at the ADI and is
also less than the 12–20 h samples from volunteers (range 1.9–4.0 µmol/mol creatinine), which might
better reflect the likely potential exposure of residents to any spray. The detection of low levels of
unhydrolysed penconazole-COOH in volunteer samples up to 48 h after dosing indicates that general
population levels are genuinely low and not due to an inability of the methodology to detect exposure.
The penconazole results and comparisons with levels predicted by regulatory models are discussed in
more detail elsewhere [6].
5. Conclusions
The work presented here demonstrates that both penconazole-COOH and penconazole-OH are
specific human metabolites of penconazole. Following hydrolysis, penconazole-OH is the major
metabolite but may be more variable between individuals compared to penconazole-COOH. The lack
of availability of a penconazole-OH standard prevented its analysis in the residents study but it is clear
that, as a major metabolite, it should be included (with hydrolysis) alongside penconazole-COOH
in any future biomonitoring studies of penconazole. The volunteer study has demonstrated that
an oral dose is readily excreted with a half-life of less than four hours. Although this half-life may
be relevant for looking at dietary exposures, the toxicokinetics for dermal exposures are likely to
be significantly delayed (due to delayed absorption). A sampling strategy that includes both end
of exposure and next day urine samples, as well as contextual data about the most likely route of
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exposure (depending on the nature of the task or incident) and the time of the exposure relative to the
samples taken is recommended.
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